Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38446 | 1.00 | HTT (0.58) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| Hydrochloric Acid SCHEMBL11278994 | 0.98 | HTT (0.57) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL561284 | 0.93 | HTT (0.64) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL8413418 | 0.92 | HTT (0.51) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| Methyl 3,5-Dinitrobenzoate SCHEMBL418416 | 0.89 | SMN1; SMN2 (0.60) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL8762477 | 0.88 | HTT (0.59) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL16960801 | 0.86 | HTT (0.58) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL4731202 | 0.86 | HTT (0.58) | HTTSMN1; SMN2GAAPOLBMEN1 | |
| SCHEMBL232779 | 0.85 | TP53 (0.64) | SMN1; SMN2POLBMEN1KMT2AMAPT | |
| SCHEMBL30917332 | 0.85 | SMN1; SMN2 (0.57) | HTTSMN1; SMN2GAAPOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115521228-B | BChE and HDAC double-target inhibitor and preparation method and application thereof | 中国药科大学 | 2023-08-22 | — | — | CN | claimed |
| CN-115521228-A | BChE and HDAC double-target inhibitor and preparation method and application thereof | 中国药科大学 | 2022-12-27 | — | — | CN | claimed |
| CN-112851537-A | Contrast agent iopromide intermediate and preparation method and application thereof | 施一新 | 2021-05-28 | — | — | CN | claimed |
| US-20250115634-A1 | LIGAND, METHOD FOR PREPARING SAME, AND USE THEREOF | LNCTAC CO., LTD. (CN) | 2025-04-10 | — | — | US | disclosed |
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-21 | — | — | US | disclosed |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-11-14 | — | — | US | disclosed |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-26 | — | — | US | disclosed |
| EP-4192812-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240270715-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-15 | — | — | US | disclosed |
| EP-4192813-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-14 | — | — | EP | disclosed |
| EP-4192814-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-08-07 | — | — | EP | disclosed |
| EP-0720601-B1 | GASTRIN AND CCK RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2000-10-25 | — | — | EP | disclosed |
| US-6127191-A | SOLID SUPPORT HAVING PLURALITY OF PENDANT SCAFFOLD MOIETIES COVALENTLY ATTACHED; FOR SYNTHESIS OF BIOACTIVE MOLECULES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | disclosed |
| US-6002041-A | Process for preparing di-C1 - C4 -alkyl 5-nitro-isophthalates | BAYER AKTIENGESELLSCHAFT (DE) | 1999-12-14 | — | — | US | disclosed |
| US-5919829-A | Gastrin and cck receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-07-06 | — | — | US | disclosed |
| US-5795907-A | Gastin and CCK receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 1998-08-18 | — | — | US | disclosed |
| US-5770380-A | Synthetic antibody mimics--multiple peptide loops attached to a molecular scaffold | UNIVERSITY OF PITTSBURGH (US) | 1998-06-23 | — | — | US | disclosed |
| WO-1998024760-A1 | AMINOBENZENEDICARBOXYLIC ACID-BASED COMBINATORIAL LIBRARIES | GRAYBILL TODD L (US) | 1998-06-11 | — | — | WO | disclosed |
| US-4138589-A | CHEMICAL INTERMEDIATES FOR COMPOUNDS USED AS X-RAY CONTRAST AGENTS | MALLINCKRODT, INC. (US) | 1979-02-06 | — | — | US | disclosed |
| US-4069250-A | X-RAY CONTRAST AGENTS | MALLINCKRODT, INC. (US) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383856-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | HTT 1201/4885SMN1; SMN2 2963/4885GAA 7/4885 |
| US-20240376055-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | HTT 1201/4885SMN1; SMN2 2963/4885GAA 7/4885 |
| US-20250115634-A1 | LIGAND, METHOD FOR PREPARING SAME, AND USE THEREOF | SIGLEC7, ASGR1, ADGRF1 | HTT 4745/4885SMN1; SMN2 4428/4885GAA 1093/4885 |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | HTT 1201/4885SMN1; SMN2 2963/4885GAA 7/4885 |
| US-20240270715-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | HTT 1201/4885SMN1; SMN2 2963/4885GAA 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.